123I-iodobenzamide SPECT is not an independent predictor of dopaminergic responsiveness in patients with suspected atypical parkinsonian syndromes

Journal of Nuclear Medicine

Volumn 54, Issue 12, 2013, Pages 2081-2086

  Hellwig, Sabine ^a   Kreft, Annabelle ^a   Amtage, Florian ^a   Tüscher, Oliver ^a,b   Winz, Oliver H ^c   Hellwig, Bernhard ^a   Weiller, Cornelius ^a   Weber, Wolfgang A ^a   Vach, Werner ^d   Meyer, Philipp T ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Atypical parkinsonian syndrome; Levodopa response; Parkinsonism

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FLUORODEOXYGLUCOSE F 18; IODOBENZAMIDE I 123; LEVODOPA; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DOPAMINE; IDOBENZAMIDE; IODOBENZENE;

AGED; ARTICLE; ATYPICAL PARKINSONIAN SYNDROME; CORRELATIONAL STUDY; CORTICOBASAL DEGENERATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOPAMINERGIC ACTIVITY; FAINTNESS; FEMALE; FOLLOW UP; HALLUCINATION; HOEHN AND YAHR SCALE; HUMAN; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROSPECTIVE STUDY; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; [123I]IBZM SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY; AGE; CLINICAL TRIAL; LEVODOPA RESPONSE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; SCINTISCANNING; TREATMENT OUTCOME; DIAGNOSTIC USE; PARKINSONIAN DISORDERS;

[123I]IBZM SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY; ATYPICAL PARKINSONIAN SYNDROME; LEVODOPA RESPONSE; PARKINSONISM;

AGE FACTORS; AGED; DOPAMINE; FEMALE; HUMANS; IODOBENZENES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARKINSONIAN DISORDERS; RECEPTORS, DOPAMINE D2; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 84893414997     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.122010     Document Type: Article

References (40)

1. Litvan I, Bhatia KP, Burn DJ, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18:467-486.
2. Constantinescu R, Richard I, Kurlan R. Levodopa responsiveness in disorders with parkinsonism: a review of the literature. Mov Disord. 2007;22:2141-2148.
3. O'Sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain. 2008;131:1362-1372.
4. Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database Syst Rev. 2010;CD007166.
5. de la Fuente-Fernández R, Schulzer M, Mak E, Sossi V. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations. Parkinsonism Relat Disord. 2010;16:365-369.
6. Henchcliffe C, Severt WL. Disease modification in Parkinson's disease. Drugs Aging. 2011;28:605-615.
7. Chen JJ. Pharmacologic safety concerns in Parkinson's disease: facts and insights. Int J Neurosci. 2011;121(suppl 2):45-52.
8. Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:968-975.
9. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71:670-676.
10. Clarke CE, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;69:590-594.
11. Parkinson's disease: diagnosis and management in primary and secondary care. National Institute for Health and Care Excellence Web site. http://publications. nice.org.uk/parkinsons-disease-cg35. Accessed September 23, 2013.
12. Schwarz J, TatschK, ArnoldG, et al. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology. 1992;42:556-561.
13. Schwarz J, Tatsch K, Arnold G, et al. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology. 1993;43(suppl 6):S17-S20.
14. Schwarz J, Tatsch K, Gasser T, Arnold G, Oertel WH. 123IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord. 1997;12:898-902.
15. Schwarz J, Tatsch K, Gasser T, et al. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord. 1998;13:16-19.
16. Hellwig S, Amtage F, Kreft A, et al. [18F]FDG-PET is superior to [123I]IBZMSPECT for the differential diagnosis of parkinsonism. Neurology. 2012;79:1314-1322.
17. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002;287:455-463.
18. Wüllner U, Kassubek J, Odin P, et al. Transdermal rotigotine for the perioperative management of Parkinson's disease. J Neural Transm. 2010;117:855-859.
19. Radau PE, Linke R, Slomka PJ, Tatsch K. Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med. 2000;41:220-227.
20. Meyer PT, Sattler B, Winz OH, et al. Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: a critical evaluation of the single-scan approach. Neuroimage. 2008;42:548-558.
21. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27:1533-1539.
22. Nakagawa M, Kuwabara Y, Taniwaki T, et al. PET evaluation of the relationship between D2 receptor binding and glucose metabolism in patients with parkinsonism. Ann Nucl Med. 2005;19:267-275.
23. Plotkin M, Amthauer H, Klaffke S, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm. 2005;112:677-692.
24. Südmeyer M, Antke C, Zizek T, et al. Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach. J Nucl Med. 2011;52:733-740.
25. Dickson DW, Ahmed Z, Algom AA, Tsuboi Y, Josephs KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010;23:394-400.
26. Jellinger KA, Seppi K, Wenning GK. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord. 2005;20(suppl 12):S29-S36.
27. Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol. 2011;7:263-272.
28. Verstappen CC, Bloem BR, Haaxma CA, Oyen WJ, Horstink MW. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. 2007;34:502-507.
29. Brücke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab. 1991;11:220-228.
30. Ichise M, Toyama H, Fornazzari L, Ballinger JR, Kirsh JC. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J Nucl Med. 1993;34:1274-1281.
31. Toyama H, Ichise M, Ballinger JR, Fornazzari L, Kirsh JC. Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans. Ann Nucl Med. 1993;7:29-38.
32. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord. 1997;12:33-38.
33. Antonini A, Vontobel P, Psylla M, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol. 1995;52:1183-1190.
34. Marek K, Jennings D, Seibyl J. Imaging the dopamine system to assess diseasemodifying drugs: studies comparing dopamine agonists and levodopa. Neurology. 2003;61:S43-S48.
35. Schwarz J, Oertel WH, Tatsch K. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-dopa. J Nucl Med. 1996;37: 1112-1115.
36. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology. 1997;49:717-723.
37. Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol. 1992;31:184-192.
38. Durso R, Isaac K, Perry L, Saint-Hilaire M, Feldman RG. Age influences magnitude but not duration of response to levodopa. J Neurol Neurosurg Psychiatry. 1993;56:65-68.
39. Granerus AK, Steg G, Svanborg A. Clinical analyses of factors influencing L-dopa treatment of Parkinson's syndrome. Acta Med Scand. 1972;192:1-11.
40. Levy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology. 2000;55:539-544.